Drug Search Results
More Filters [+]

ATYR 1940

Alternative Names: atyr 1940, atyr1940
Latest Update: 2023-12-22
Latest Update Note: Clinical Trial Update

Product Description

aTyr 1940 is a recombinant 506 amino acid version of human histidyl-tRNA synthetase (cytoplasmic isoform 1) (HARS; P12081) [1]. HARS belongs to a novel group of naturally occurring proteins termed 'physiocrines' which are extracellular signaling regions of tRNA synthetases reported to modulate immune system pathways.  (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=8738)

Mechanisms of Action: RNA Synthetase Analogue

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: aTyr Pharma
Company Location: SAN DIEGO CA 92121
Company CEO: Sanjay S. Shukla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ATYR 1940

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Muscular Dystrophy, Facioscapulohumeral|Muscular Dystrophies, Limb-Girdle

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

RNN/246/20/KE

N/A

Not yet recruiting

Osteoarthritis|Carpal Tunnel Syndrome

2029-06-15

FSHD

P2

Completed

Muscular Dystrophy, Facioscapulohumeral|Muscular Dystrophies, Limb-Girdle

2017-04-18

2016-000624-25

P2

Terminated

Muscular Dystrophies, Limb-Girdle|Muscular Dystrophy, Facioscapulohumeral

2017-04-18

2014-001753-17

P2

Completed

Muscular Dystrophy, Facioscapulohumeral

2017-01-04

Recent News Events